drug_name	trade_name	drug_class	entrez_gene_name	primary_gene_name	metadata_fda_approval
Ado-trastuzumab emtansine 	Kadcyla	Monoclonal antibody	ERBB2	ERBB2	Breast cancer (HER2+)
Afatinib 	Gilotrif	TKI	EGFR 	EGFR 	Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
Alectinib 	Alecensa	TKI	ALK	ALK	Non-small cell lung cancer (with ALK fusion)
Alemtuzumab 	Campath	Monoclonal antibody	CD52	CD52	B-cell chronic lymphocytic leukemia
Atezolizumab 	Tecentriq	Monoclonal antibody	CD274	PD-L1	Non-small cell lung cancer, Urothelial carcinoma
Avelumab 	Bavencio	Monoclonal antibody	CD274	PD-L1	Merkel cell carcinoma
Axitinib 	Inlyta	TKI	KIT	KIT	Renal cell carcinoma
Axitinib 	Inlyta	TKI	PDGFRB	PDGFRB	Renal cell carcinoma
Axitinib 	Inlyta	TKI	VEGFR1	VEGFR1	Renal cell carcinoma
Axitinib 	Inlyta	TKI	VEGFR2	VEGFR2	Renal cell carcinoma
Axitinib 	Inlyta	TKI	VEGFR3	VEGFR3	Renal cell carcinoma
Belimumab 	Benlysta	Monoclonal antibody	TNFSF13B	BAFF	Lupus erythematosus
Belinostat 	Beleodaq		HDAC1	HDAC	Peripheral T-cell lymphoma
Belinostat 	Beleodaq		HDAC4	HDAC	Peripheral T-cell lymphoma
Belinostat 	Beleodaq		HDAC7	HDAC	Peripheral T-cell lymphoma
Belinostat 	Beleodaq		HDAC9	HDAC	Peripheral T-cell lymphoma
Bevacizumab 	Avastin	Monoclonal antibody	VEGFA	VEGF	Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma
Bortezomib 	Velcade	Small molecule inhibitor	PSMC5	Proteasome	Multiple myeloma, Mantle cell lymphoma
Bosutinib 	Bosulif	TKI	ABL1	ABL	Chronic myelogenous leukemia (Philadelphia chromosome positive)
Brentuximab vedotin 	Adcetris	Chimeric antibody	CD30	CD30	Hodgkin lymphoma, Anaplastic large cell lymphoma
Cabozantinib 	Cabometyx [tablet], Cometriq [capsule]	TKI	KIT	KIT	Medullary thyroid cancer, Renal cell carcinoma
Cabozantinib 	Cabometyx [tablet], Cometriq [capsule]	TKI	MET	MET	Medullary thyroid cancer, Renal cell carcinoma
Cabozantinib 	Cabometyx [tablet], Cometriq [capsule]	TKI	RET	RET	Medullary thyroid cancer, Renal cell carcinoma
Cabozantinib 	Cabometyx [tablet], Cometriq [capsule]	TKI	VEGFR2	VEGFR2	Medullary thyroid cancer, Renal cell carcinoma
Cabozantinib 	Cabometyx [tablet], Cometriq [capsule]	TKI	FLT3	FLT3	Medullary thyroid cancer, Renal cell carcinoma
Canakinumab 	Ilaris	Monoclonal antibody	IL1B	IL1B	Juvenile idiopathic arthritis
Carfilzomib 	Kyprolis	Small molecule inhibitor	PSMC5	Proteasome	Multiple myeloma
Ceritinib 	Zykadia	TKI	ALK	ALK	Non-small cell lung cancer (with ALK fusion)
Cetuximab 	Erbitux	Chimeric antibody	EGFR 	EGFR 	Colorectal cancer (KRAS wild type), Squamous cell carcinoma of the head and neck
Cobimetinib 	Cotellic	TKI	MEK	MEK	Melanoma (with BRAF V600E or V600K mutation)
Crizotinib 	Xalkori	TKI	ROS1	ROS1	Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration)
Crizotinib 	Xalkori	TKI	MET	MET	Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration)
Crizotinib 	Xalkori	TKI	ALK	ALK	Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration)
Dabrafenib 	Tafinlar	Small molecule inhibitor	BRAF	BRAF	Melanoma (with BRAF V600 mutation)
Daratumumab 	Darzalex	Human monoclonal antibody	CD38	CD38	Multiple myeloma
Dasatinib 	Sprycel	TKI	ABL1	ABL	Chronic myelogenous leukemia (Philadelphia chromosome positive), Acute lymphoblastic leukemia (Ph +)
Denosumab 	Xgeva	Monoclonal antibody	RANKL	RANKL	Giant cell tumor of the bone
Dinutuximab 	Unituxin	Chimeric antibody	B4GALNT1 	B4GALNT1 	Pediatric neuroblastoma
Elotuzumab 	Empliciti	Monoclonal antibody	SLAMF7 	SLAMF7 	Multiple myeloma
Erlotinib 	Tarceva	TKI	EGFR 	EGFR 	Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations), Pancreatic cancer
Everolimus 	Afinitor		MTOR	mTOR	Pancreatic, gastrointestinal, or lung origin neuroendocrine tumors; Renal cell carcinoma, Subependymal giant cell astrocytoma associated with tuberous sclerosis, Breast cancer (ER+, HER2-)
Gefitinib 	Iressa	TKI	EGFR 	EGFR 	Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
Ibritumomab tiuxetan 	Zevalin	Monoclonal antibody	CD20	CD20	Non-Hodgkin's lymphoma
Ibrutinib 	Imbruvica	TKI	BTK	BTK	Mantle cell lymphoma, Chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia
Idelalisib 	Zydelig		PIK3CD	PI3Kδ	Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma
Imatinib 	Gleevec	TKI	ABL1	ABL	GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML
Imatinib 	Gleevec	TKI	PDGFRA	PDGFR	GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML
Imatinib 	Gleevec	TKI	PDGFRB	PDGFR	GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML
Imatinib 	Gleevec	TKI	KIT	KIT	GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML
Ipilimumab 	Yervoy	Human monoclonal antibody	CTLA4	CTLA-4	Melanoma
Ixazomib 	Ninlaro	Small molecule inhibitor	PSMC5	Proteasome	Multiple Myeloma
Lapatinib 	Tykerb	TKI	ERBB2	HER2 	Breast cancer (HER2+)
Lenvatinib 	Lenvima	TKI	VEGFR2	VEGFR2	Renal cell carcinoma, Thyroid cancer
Necitumumab 	Portrazza	Human monoclonal antibody	EGFR 	EGFR 	Squamous non-small cell lung cancer
Nilotinib 	Tasigna	TKI	ABL1	ABL	Chronic myelogenous leukemia (Philadelphia chromosome positive)
Niraparib 	Zejula	Small molecule inhibitor	PARP1	PARP	Ovarian cancer, Fallopian tube cancer, Peritoneal cancer
Nivolumab 	Opdivo	Monoclonal antibody	PDCD1	PD-1	Head and neck squamous cell carcinoma, Hodgkin lymphoma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urothelial carcinoma
Obinutuzumab 	Gazyva	Monoclonal antibody	CD20	CD20	Chronic lymphocytic leukemia, Follicular lymphoma
Ofatumumab 	Arzerra, HuMax-CD20	Human monoclonal antibody	CD20	CD20	Chronic lymphocytic leukemia
Olaparib 	Lynparza	Small molecule inhibitor	PARP	PARP	Ovarian cancer (with BRCA mutation)
Olaratumab 	Lartruvo	Monoclonal antibody	PDGFRA	PDGFRA	Soft tissue sarcoma
Osimertinib 	Tagrisso	TKI	EGFR	EGFR	Non-small cell lung cancer (with EGFR T790M mutation)
Palbociclib 	Ibrance	Small molecule inhibitor	CDK6	CDK6	Breast cancer (HR+, HER2-)
Palbociclib 	Ibrance	Small molecule inhibitor	CDK4	CDK4	Breast cancer (HR+, HER2-)
Panitumumab 	Vectibix	Human monoclonal antibody	EGFR 	EGFR 	Colorectal cancer (KRAS wild type)
Panobinostat 	Farydak		HDAC1	HDAC	Multiple myeloma
Panobinostat 	Farydak		HDAC4	HDAC	Multiple myeloma
Panobinostat 	Farydak		HDAC7	HDAC	Multiple myeloma
Panobinostat 	Farydak		HDAC9	HDAC	Multiple myeloma
Pazopanib 	Votrient	Small molecule inhibitor	KIT	KIT	Renal cell carcinoma
Pazopanib 	Votrient	Small molecule inhibitor	PDGFRA	PDGFR	Renal cell carcinoma
Pazopanib 	Votrient	Small molecule inhibitor	VEGFR1	VEGFR1	Renal cell carcinoma
Pembrolizumab 	Keytruda	Monoclonal antibody	PDCD1	PD-1	Classical Hodgkin lymphoma, Melanoma, Non-small cell lung cancer (PD-L1+), Head and neck squamous cell carcinoma
Pertuzumab 	Perjeta	Monoclonal antibody	ERBB2	HER2 	Breast cancer (HER2+)
Ponatinib 	Iclusig	TKI	FGFR1	FGFR1	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ponatinib 	Iclusig	TKI	FGFR2	FGFR2	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ponatinib 	Iclusig	TKI	FGFR3	FGFR3	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ponatinib 	Iclusig	TKI	FLT3	FLT3	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ponatinib 	Iclusig	TKI	VEGFR2	VEGFR2	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ponatinib 	Iclusig	TKI	ABL1	ABL	Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Ramucirumab 	Cyramza	Monoclonal antibody	VEGFR2	VEGFR2	Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer
Regorafenib 	Stivarga	TKI	PDGFRB	PDGFRB	Colorectal cancer, Gastrointestinal stromal tumors
Regorafenib 	Stivarga	TKI	KIT	KIT	Colorectal cancer, Gastrointestinal stromal tumors
Ribociclib 	Kisqali		CDK6	CDK6	Breast cancer (HR+, HER2-)
Ribociclib 	Kisqali		CDK4	CDK4	Breast cancer (HR+, HER2-)
Rituximab 	Rituxan, Mabthera	Monoclonal antibody	CD20	CD20	Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis
Romidepsin 	Istodax		HDAC1	HDAC	Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
Romidepsin 	Istodax		HDAC4	HDAC	Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
Romidepsin 	Istodax		HDAC7	HDAC	Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
Romidepsin 	Istodax		HDAC9	HDAC	Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
Rucaparib 	Rubraca		PARP1	PARP	Ovarian cancer (with BRCA mutation)
Ruxolitinib 	Jakafi	TKI	JAK2	JAK2	​Myelofibrosis
Ruxolitinib 	Jakafi	TKI	JAK1	JAK1	​Myelofibrosis
Siltuximab 	Sylvant	Monoclonal antibody	IL6	IL-6	Multicentric Castleman's disease
Sonidegib 	Odomzo		SMO	SMO	Basal cell carcinoma
Sorafenib 	Nexavar	TKI	BRAF	RAF	Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
Sorafenib 	Nexavar	TKI	KIT	KIT	Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
Sorafenib 	Nexavar	TKI	PDGFRB	PDGFRB	Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
Sorafenib 	Nexavar	TKI	VEGFR1	VEGFR1	Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
Temsirolimus 	Torisel		MTOR	mTOR	Renal cell carcinoma
Tocilizumab 	Actemra	Monoclonal antibody	IL6R	IL-6R	Rheumatoid arthritis, Juvenile idiopathic arthritis
Tofacitinib 	Xeljanz	TKI	JAK3	JAK3	Rheumatoid arthritis
Tositumomab 	Bexxar	Monoclonal antibody	CD20	CD20	Non-Hodgkin's lymphoma
Trametinib 	Mekinist	TKI	MEK	MEK	Melanoma (with BRAF V600 mutation)
Trastuzumab 	Herceptin	Monoclonal antibody	ERBB2	HER2 	Breast cancer (HER2+), Gastric cancer (HER2+)
Vandetanib 	Caprelsa	TKI	EGFR 	EGFR 	Medullary thyroid cancer
Vemurafenib 	Zelboraf	TKI	BRAF	BRAF	Melanoma (with BRAF V600 mutation)
Venetoclax 	Venclexta		BCL2	BCL2	Chronic lymphocytic leukemia (with 17p deletion)
Vismodegib 	Erivedge		PTCH1	PTCH1	Basal cell carcinoma
Vismodegib 	Erivedge		SMO	SMO	Basal cell carcinoma
Vorinostat 	Zolinza		HDAC1	HDAC	Cutaneous T-cell lymphoma
Vorinostat 	Zolinza		HDAC4	HDAC	Cutaneous T-cell lymphoma
Vorinostat 	Zolinza		HDAC7	HDAC	Cutaneous T-cell lymphoma
Vorinostat 	Zolinza		HDAC9	HDAC	Cutaneous T-cell lymphoma
Ziv-aflibercept 	Zaltrap		PIGF	PIGF	Colorectal cancer
Ziv-aflibercept 	Zaltrap		VEGFR1	VEGFR1	Colorectal cancer
Ziv-aflibercept 	Zaltrap		VEGFR2	VEGFR2	Colorectal cancer